Rob Wallis
Overview
Explore the profile of Rob Wallis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Milliken P, Aylott M, Edmunds N, Engle S, Ewart L, Fleurance R, et al.
Toxicol Sci
. 2020 Apr;
176(1):224-235.
PMID: 32298455
Integrating nonclinical in vitro, in silico, and in vivo datasets holistically can improve hazard characterization and risk assessment. In pharmaceutical development, cardiovascular liabilities are a leading cause of compound attrition....
2.
Fletcher S, Maddock H, James R, Wallis R, Gharanei M
Sci Rep
. 2020 Mar;
10(1):5258.
PMID: 32210283
The cardiac work-loop technique closely mimics the intrinsic in vivo movement and characteristics of cardiac muscle function. In this study, six known inotropes were profiled using the work-loop technique to...
3.
Pereira P, Pugsley M, Troncy E, Tan W, Pouliot M, Harper C, et al.
J Pharmacol Toxicol Methods
. 2019 Jun;
99:106589.
PMID: 31154034
Spontaneous arrhythmia characterization in healthy rats can support interpretation when studying novel therapies. Male (n = 55) and female (n = 40) Sprague-Dawley rats with telemetry transmitters for a derivation...
4.
Wallis R, Benson C, Darpo B, Gintant G, Kanda Y, Prasad K, et al.
J Pharmacol Toxicol Methods
. 2018 Jul;
93:15-25.
PMID: 29958940
The Safety Pharmacology Society organized a scientific session at its annual conference in 2017 to discuss the challenges and opportunities of the Comprehensive In-Vitro Proarrhythmia Assay (CiPA) paradigm. Our intention...
5.
Wallis R, Gharanei M, Maddock H
J Pharmacol Toxicol Methods
. 2015 Jun;
75:62-9.
PMID: 26026903
Adverse drug effects on the cardiovascular system are a major cause of compound attrition throughout compound discovery and development. There are many ways by which drugs can affect the cardiovascular...
6.
Ewart L, Aylott M, Deurinck M, Engwall M, Gallacher D, Geys H, et al.
Toxicol Sci
. 2014 Sep;
142(2):427-35.
PMID: 25246669
It is widely accepted that more needs to be done to bring new, safe, and efficacious drugs to the market. Cardiovascular toxicity detected both in early drug discovery as well...
7.
Ewart L, Gallacher D, Gintant G, Guillon J, Leishman D, Levesque P, et al.
J Pharmacol Toxicol Methods
. 2012 Apr;
66(2):66-70.
PMID: 22510338
Introduction: How does safety pharmacology operate in large pharmaceutical companies today? By understanding our current position, can we prepare safety pharmacology to successfully navigate the complex process of drug discovery...
8.
Percie du Sert N, Holmes A, Wallis R, Andrews P
Br J Pharmacol
. 2011 Sep;
165(6):1848-1867.
PMID: 21913900
Background And Purpose: Emesis is a multi-system reflex, which is usually investigated using in vivo models. The aim of the study is to compare the response induced by emetic compounds...
9.
Bass A, Vargas H, Valentin J, Kinter L, Hammond T, Wallis R, et al.
J Pharmacol Toxicol Methods
. 2011 Jun;
64(1):7-15.
PMID: 21689769
In recognition of the tenth anniversary of the Safety Pharmacology Society (SPS), this review summarizes the significant events of the past 10years that have led to the birth, growth and...
10.
Gorman K, Handrigan G, Jin G, Wallis R, Breden F
Scoliosis
. 2010 Jun;
5:10.
PMID: 20529276
Background: The curveback lineage of guppy is characterized by heritable idiopathic-type spinal curvature that develops during growth. Prior work has revealed several important developmental similarities to the human idiopathic scoliosis...